Donald McDonnell: Lasofoxifene will finally find its use in the treatment of metastatic breast cancer

Donald McDonnell, Professor at the Department of Pharmacology and Cancer Biology, Duke University School of Medicine, shared a post on LinkedIn by Deborah Borfitz, Senior Science Writer at Cambridge Healthtech Institute, adding:

“There is an old saying in the pharmaceutical industry that ‘all good drugs fail at least three times’.

This and other studies from our group suggest that lasofoxifene (a SERM) will finally find its use in the treatment of metastatic breast cancer and other cancers which the immune system can be tricked into attacking.

Thank you Deborah for your interest in our work.”

Quoting Deborah Borfitz’s post:

“You don’t have to be a Duke scientist to know the importance of finding better ways to treat triple-negative breast cancer, but it doesn’t hurt if you’re Donald McDonnell who has been a pioneer in the field for decades.

His latest feat centers on a one-time osteoporosis drug that inhibits rather than degrades the estrogen receptor, which might further improve the pathological complete response rate of patients to treatment. Read all about it!”